Skip to main content

Table 2 Unweighted and weighted fracture rates in 1, 3, 5, 6, 7, 8 years of adherent treatment with RLX and ALN

From: Fractures in women treated with raloxifene or alendronate: a retrospective database analysis

Length of followup Before propensity weighting After propensity weighting
RLX ALN P-value RLX ALN P-value
  % Lower 95% CI Upper 95% CI % Lower 95% CI Upper 95% CI   % Lower 95% CI Upper 95% CI % Lower 95% CI Upper 95% CI  
Vertebral Fracture               
1-year 0.19% 0.13% 0.25% 0.30% 0.27% 0.35% 0.002 0.34% 0.31% 0.38% 0.30% 0.27% 0.34% 0.334
3-years 0.67% 0.50% 0.83% 1.00% 0.89% 1.14% 0.002 0.93% 0.83% 1.03% 0.97% 0.87% 1.08% 0.720
5-years 0.92% 0.59% 1.26% 1.70% 1.40% 2.03% 0.002 1.48% 1.25% 1.71% 1.69% 1.43% 1.94% 0.451
6-years 1.20% 0.60% 1.81% 1.99% 1.44% 2.54% 0.083 1.28% 0.93% 1.64% 1.90% 1.46% 2.34% 0.169
7-years 1.38% 0.49% 2.28% 3.10% 2.08% 4.19% 0.024 2.14% 1.46% 2.82% 3.11% 2.29% 3.94% 0.231
8-years 0.92% 0.00% 2.19% 3.32% 1.39% 5.25% 0.071 3.70% 2.12% 5.27% 3.80% 2.19% 5.41% 0.952
Nonvertebral Fracture               
1-year 1.96% 1.78% 2.14% 2.20% 2.10% 2.31% 0.023 2.36% 2.27% 2.45% 2.15% 2.06% 2.24% 0.056
3-years 6.48% 5.99% 6.97% 6.80% 6.48% 7.12% 0.281 7.31% 7.04% 7.58% 6.70% 6.40% 6.93% 0.034
5-years 9.71% 8.67% 10.75% 11.80% 11.05% 12.61% 0.002 10.73% 10.14% 11.33% 11.48% 10.85% 12.12% 0.271
6-years 12.36% 10.53% 14.19% 13.18% 11.85% 14.52% 0.479 13.99% 12.89% 15.10% 12.99% 11.90% 14.07% 0.395
7-years 13.85% 11.19% 16.50% 15.29% 13.12% 17.46% 0.414 17.53% 15.74% 19.32% 15.29% 13.58% 17.01% 0.222
8-years 15.67% 10.83% 20.50% 18.73% 14.53% 22.93% 0.356 12.97% 10.16% 15.78% 18.82% 15.53% 22.12% 0.071
  1. ALN=alendronate; RLX=raloxifene.